These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 39370840)

  • 21. Advances in the long-term treatment of neuromyelitis optica spectrum disorder.
    Anderson M; Levy M
    J Cent Nerv Syst Dis; 2024; 16():11795735241231094. PubMed ID: 38312734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.
    Wingerchuk DM; Zhang I; Kielhorn A; Royston M; Levy M; Fujihara K; Nakashima I; Tanvir I; Paul F; Pittock SJ
    Neurol Ther; 2022 Mar; 11(1):123-135. PubMed ID: 34773597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder.
    Clardy SL; Pittock SJ; Aktas O; Nakahara J; Isobe N; Centonze D; Fam S; Kielhorn A; Yu JC; Jansen J; Zhang I
    Neurol Ther; 2024 Jun; 13(3):535-549. PubMed ID: 38722571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Satralizumab in the treatment of neuromyelitis optica spectrum disorder.
    Duchow A; Bellmann-Strobl J
    Neurodegener Dis Manag; 2021 Feb; 11(1):49-59. PubMed ID: 33167776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Case report: Transition from anti-CD20 therapy to inebilizumab for 14 cases of neuromyelitis optica spectrum disorder.
    Osborne B; Romanow G; Hemphill JM; Zarif M; DeAngelis T; Kaplan T; Oh U; Pinkhasov J; Patterson K; Levy M
    Front Neurol; 2024; 15():1352779. PubMed ID: 38689876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamic modelling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders.
    Yan L; Wang B; She D; Mitchell B; Criste R; Cimbora D; Katz E; Rees WA
    Br J Clin Pharmacol; 2022 Aug; 88(8):3803-3812. PubMed ID: 35332558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report.
    Lehrieder D; Zapantis N; Pham M; Schuhmann MK; Haarmann A
    Front Neurol; 2023; 14():1297341. PubMed ID: 38073644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
    Fung S; Shirley M
    CNS Drugs; 2023 Apr; 37(4):363-370. PubMed ID: 36933107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of complement and complement therapeutics in neuromyelitis optica spectrum disorders.
    Stathopoulos P; Dalakas MC
    Expert Rev Clin Immunol; 2022 Sep; 18(9):933-945. PubMed ID: 35899480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
    Yamamura T; Kleiter I; Fujihara K; Palace J; Greenberg B; Zakrzewska-Pniewska B; Patti F; Tsai CP; Saiz A; Yamazaki H; Kawata Y; Wright P; De Seze J
    N Engl J Med; 2019 Nov; 381(22):2114-2124. PubMed ID: 31774956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials.
    Xue T; Yang Y; Lu Q; Gao B; Chen Z; Wang Z
    Mult Scler Relat Disord; 2020 Aug; 43():102166. PubMed ID: 32442886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B cell and aquaporin-4 antibody relationships with neuromyelitis optica spectrum disorder activity.
    Bennett JL; Pittock SJ; Paul F; Kim HJ; Irani SR; O'Connor KC; Patterson KR; Smith MA; Gunsior M; Mittereder N; Rees WA; Cimbora D; Cree BAC
    Ann Clin Transl Neurol; 2024 Oct; 11(10):2792-2798. PubMed ID: 39222408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials.
    Pittock SJ; Zekeridou A; Weinshenker BG
    Nat Rev Neurol; 2021 Dec; 17(12):759-773. PubMed ID: 34711906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Neuromyelitis Optica Spectrum Disorder].
    Misu T
    Brain Nerve; 2021 May; 73(5):475-482. PubMed ID: 34006678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders.
    Ringelstein M; Ayzenberg I; Lindenblatt G; Fischer K; Gahlen A; Novi G; Hayward-Könnecke H; Schippling S; Rommer PS; Kornek B; Zrzavy T; Biotti D; Ciron J; Audoin B; Berthele A; Giglhuber K; Zephir H; Kümpfel T; Berger R; Röther J; Häußler V; Stellmann JP; Whittam D; Jacob A; Kraemer M; Gueguen A; Deschamps R; Bayas A; Hümmert MW; Trebst C; Haarmann A; Jarius S; Wildemann B; Grothe M; Siebert N; Ruprecht K; Paul F; Collongues N; Marignier R; Levy M; Karenfort M; Deppe M; Albrecht P; Hellwig K; Gold R; Hartung HP; Meuth SG; Kleiter I; Aktas O;
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34785575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment and new evidences in neuromyelitis optica spectrum disorder].
    Illés Z
    Ideggyogy Sz; 2021 Sep; 74(9-10):309-321. PubMed ID: 34657404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An update on biologic treatments for neuromyelitis optica spectrum disorder.
    Kim W; Kim HJ
    Expert Rev Clin Immunol; 2023 Jan; 19(1):111-121. PubMed ID: 36414430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
    Kümpfel T; Giglhuber K; Aktas O; Ayzenberg I; Bellmann-Strobl J; Häußler V; Havla J; Hellwig K; Hümmert MW; Jarius S; Kleiter I; Klotz L; Krumbholz M; Paul F; Ringelstein M; Ruprecht K; Senel M; Stellmann JP; Bergh FT; Trebst C; Tumani H; Warnke C; Wildemann B; Berthele A;
    J Neurol; 2024 Jan; 271(1):141-176. PubMed ID: 37676297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.